Current Status
Not Enrolled
Get Started

Ambulatory Glucose Profile and Time in Range: Essential Tools to Manage Your Patient with Diabetes

Recorded April 16, 2021


Treatment of patients with diabetes is a balance between good glycemic control and the risk of hypoglycemia. Fluctuations in the blood glucose level are common but are often missed with fingerstick blood glucose monitoring. This limitation can be overcome with continuous glucose monitoring systems, however challenges interpreting the large amount of data provided by CGM systems have limited their clinical application. This session will explore the recent guidelines on CGM which should simplify its use in clinical practice with the benefit of reducing fluctuations in the blood glucose level.


  • Identify patients who are better candidates for continuous glucose monitoring versus fingerstick blood glucose monitoring.
  • List the types of information provided by continuous glucose monitoring systems.
  • Interpret CGM data using the AGP to assess if the patient is achieving targets established by the International Consensus on Time in Range.
  • Modify the treatment plan based on CGM data to improve patient outcomes.


Stephen Brunton, MD, FAAFP
Associate Professor
Touro University California
College of Osteopathic Medicine
Vallejo, CA

Read Bio



Stephen Brunton, MD, FAAFP, has disclosed that he is on the advisory board for Abbott Diabetes, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi and Xeris Pharmaceuticals; as well as on the speakers bureau for Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk, and Sanofi.

Davida Kruger, MSN, APRN-BC, BC-ADM, Planner, has disclosed that she is on the advisory board for Novo Nordisk, Abbott, Lilly, Sanofi and Pendulum Therapeutics; as well as on the speakers bureau for Novo Nordisk, Dexcom, Lilly, Abbott and Xeris.

Jay Shubrook, DO, Planner, has disclosed that he is on the advisory board for Lilly, Novo Nordisk, Sanofi and Bayer.

Gregory Scott, PharmD, RPh, Editorial Support, disclosed no relevant financial relationship or interest with a proprietary entity producing, marketing, reselling or distributing health care goods or services.

All relevant financial relationships have been mitigated.

This CME activity includes discussion about uses of medications outside of their approved labeling.

Course Content

Thank you for attending 2021 FamMed Forum!

Thank you for participating in the 2021 FamMed Forum. In order to complete this course and qualify for CME Credit, you must be logged into the website.

If the banner above shows "log in to enroll," please do so using the BLUE login button displayed on this page. All registered attendees for the live FamMed Forum are also enrolled in each FamMed Forum stand alone CME Course.

Begin by completing the Pre-test.  Then watch the entire video lesson.  Then complete the Post-test and proceed to Session Evaluation.  Make sure you click "Submit" at the end of the evaluation before continuing to the claim for CME Credit.

Then complete the brief post-test.  If you experience difficulty, please view the Site Navigation menu item.

Each recorded session will issue a separate CME Certificate.  We are only offering AMA PRA Category 1 Credit(s)tm for the recorded stand-alone sessions.

If you have any difficulty or questions, please contact us by email by clicking here.